At Identifying previously unrecognized druggable protein targets for the treatment of diseases with limited therapeutic options, and b) develop small molecule or natural-based products to inhibit those targets.
We employ advanced technologies as well as old-fashioned hypothesis-based trial-and-error techniques to determine the role of a protein target in promoting and sustaining a disease state. Once a novel target has been identified we utilize our medicinal chemistry expertise to design small molecule inhibitors.
Our areas of interest include diseases characterized by aberrant inflammation, fibrotic diseases, and cancer. We have formed a number of collaborations (note: link this to the collaborations link) in order to further our understanding of the pathophysiological role of our targets and utilize reliable CROs to advance the preclinical development of our products.